

Saeed O et al. Effect of Aspirin Dose on Hemocompatibility-Related Outcomes with a Magnetically Levitated Left Ventricular Assist Device: An Analysis From the MOMENTUM 3 Study. *J Heart Lung Transplant.*

**STUDY HIGHLIGHTS**

**Question:** Is there a difference between usual dose (325 mg) and low dose (81 mg) ASA on hemocompatibility-related adverse events (HRAEs) in HM3 patients?


**Design:** Exploratory post-hoc analysis of MOMENTUM 3

**Inclusion:** 321 HM3 patients on warfarin (INR goal 2-3)

**Outcomes:** Survival free from HRAEs (non-surgical bleeding, pump thrombosis, stroke, and peripheral arterial thromboembolic events) at 2 years

**Results:** **No difference** in HRAEs (43.4% vs 45.3%, p=0.94). Similar rates of bleeding and thrombosis.


**CENTRAL FIGURES**



No difference in **hemorrhagic** events

No difference in **thrombotic** events

**ARIES** trial (RCT ASA vs. none in HM3) starting soon



**REVIEWER'S COMMENTS**

- Comparable INR values at time of HRAE
- ASA regimen could be changed at discretion of treating physician
- Patients that received low dose ASA were older and destination therapy (DT)
- 13% of patients excluded due to no ASA at 7-days post implant

**Limitations:**

- Unplanned post-hoc exploratory analysis
- Not powered to detect differences in outcomes
- Selection bias as older and DT patients received low dose

Vieira JL et al. The impact of statin therapy on neurological events following left ventricular assist system implantation in advanced heart failure. *J Heart Lung Transplant.*

**STUDY HIGHLIGHTS**

**Hypothesis:** Statins may ↓ rates of neurological events (i.e. stroke) following CF-LVAS

**Design:** Single-center, retrospective, observational

**Inclusion:** HMII (n=117), HVAD (n=45), HM3 (n=38); 2008-2018; index hospital survival


**Outcomes:** stroke (ischemic or hemorrhagic), TIA, delirium

**Results:** Statin assoc. with ↓ neuro events (particularly ischemic stroke if HM3 excluded)

**CENTRAL FIGURE**

**HMII + HVAD + HM3**

**Any neurological event**



**HM II + HVAD (excluding HM3)**

Any neurological event: HR 0.43 (95% CI, 0.21 to 0.86),  $p = 0.018$   
 Ischemic Stroke: HR 0.38 (95% CI, 0.15 to 0.99),  $p = 0.048$

**REVIEWER'S COMMENTS**

- Statin use = filled  $\geq 2$  Rx within 6 months after index discharge
- Comparable aspirin/INR, BP between groups
- Statin group with less events despite higher CHAD2DS2-VASc score
- HM3 lack of effect due to lower numbers vs. less benefit (lower risk)?

**Limitations:**

- Single center, retrospective
- HMII >50% of population
- Unknown cross-over of statin use